Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

Biotest Aktiengesellschaft

Körber is an international technology group that focuses on transforming entrepreneurial thinking into customer success and shaping technological change. The company employs over 12,000 people at more than 100 locations worldwide.

Körber

biosyn Arzneimittel GmbH is involved in the pharmaceutical and biotech sectors, specializing in trace elements, particularly high-dose selenium injections, and operates unique GMP-active ingredient manufacturing plants.

biosyn Arzneimittel GmbH

Biotest AG is involved in the fields of hematology, clinical immunology, and intensive medicine, offering plasma-derived products and therapeutic innovations.

Metric
Company Name	Biotest Aktiengesellschaft	Körber	biosyn Arzneimittel GmbH
Symbol	BIO
MSH ID	COM:BIOTEST	COM:KOERBER	DE:BIOSYN
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Technology	Healthcare & Health Services
Industry	Biotechnology	Technology and Engineering	Pharmaceuticals
Country	DE	DE	DE
Stage
Employee Count	2.43K
Website	biotest.com	koerber.com	biosyn.de
LinkedIn		k%C3%B6rber	biosyn-arzneimittel-gmbh
Founders

Metric
Market Cap	1.48B
Enterprise Value
Monthly Web Traffic		1.46K
Web Traffic Growth		0.82
Valuation
Raised Capital

Metric
Revenue	723.10M
Revenue (LTM)
Revenue (NTM)
Gross Profit	287.19M
EBITDA	175.44M
Operating Income	137.52M
Net Income	134.14M
EPS	3.39
Diluted EPS	3.39
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.47
Operating Profit Margin	0.30
EBITDA Margin	0.24
Net Profit Margin	0.25
Return on Equity	0.49
Return on Assets	0.14
Return on Capital Employed	0.23

COM:BIOTEST

Biotest AG

Last Close

41.60

25/11 08:02

Market Cap

1.40B

Beta: -

Volume Today

10

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	14.10
P/B Ratio	3.64
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.02
EV Multiple	4.82

Metric
Days Sales Outstanding	135.95
Days Payables Outstanding	48.60
Days Inventory Outstanding	399.31
Operating Cycle	484.24
Cash Conversion Cycle	428.00
Asset Turnover	0.59

Metric
Operating Cash Flow	-1.69M
Free Cash Flow	-36.97M
Cash Flow to Debt	0.19
Operating Cash Flow/Sales	0.15
Free Cash Flow Yield	-0.07

Metric
Cash & Equivalents	125.16M
Accounts Receivable
Inventory	442.67M
Goodwill	6.34M
Debt to Capitalization	0.60
Debt to Assets
Current Ratio	5.00
Quick Ratio	2.26

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.08
SG&A to Revenue	0.05